Researchers suggest people taking Ozempic and similar drugs may face double the risk of developing wet age-related macular ...

GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only ...

The weight loss and diabetes drug, which is only available on prescription, should be on pharmacy shelves within days ending ...

Detailed Phase IIIb STEP UP trial results presented at the 2025 ADA Scientific Sessions found that an investigational 7.2 mg dose of Wegovy (semaglutide) led to a mean weight loss of 21% in adults ...

Beyond helping diabetes patients lose weight and control blood sugar, semaglutide appears to cut dementia risk by nearly half ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Ozempic is a prescription medication made by Novo Nordisk and primarily used to treat patients with type 2 diabetes.

Researchers found that the active ingredient in Ozempic may lower the risk of dementia in people with type 2 diabetes.

Universal access to GLP-1 receptor agonists for eligible populations could reduce global obesity prevalence by half and save ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

Learn about Ozempic and Wegovy, two medications making waves in weight management. Discover how they work, their benefits, ...

Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...